Invivyd Inc. has announced plans to engage with the U.S. Food and Drug Administration (FDA) on an expedited pathway to develop next-generation COVID-19 prevention and treatment options. This initiative comes as the FDA acknowledges uncertainties in the efficacy of current COVID-19 vaccine boosters and aligns with Invivyd's Citizen Petition requests. The company aims to advance its monoclonal antibody therapies, including the investigational mAb VYD2311, to provide scalable and high-quality protection against modern immune-evasive SARS-CoV-2 viruses. Invivyd anticipates a clinical update on VYD2311 this quarter, marking a significant step in addressing the ongoing challenges posed by COVID-19, especially for high-risk populations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。